Literature DB >> 18161482

The vascular actions of relaxin.

Arundhathi Jeyabalan1, Sanjeev G Shroff, Jaqueline Novak, Kirk P Conrad.   

Abstract

Relaxin is emerging as a hormone with important vascular actions. Much of our recently gained knowledge of relaxin in this context has stemmed from investigations of maternal vascular adaptations to pregnancy in which the hormone is turning out to be an important mediator. This chapter is separated into three parts. In Part 1, we discuss relaxin in the setting of normal vascular function and focus on systemic hemodynamics and arterial mechanical properties, renal and other peripheral circulations, angiogenesis, as well as the cellular mechanisms of the vasodilatory actions of relaxin. In this section, we also summarize the evidence for an arterial-derived relaxin ligand-receptor system. In Part 2, we present relaxin in the context of vascular dysfunction and the implications for relaxin as a therapeutic agent in renal and cardiac diseases, ischemia and reperfusion injury, pulmonary hypertension, vascular inflammation and preeclampsia. Finally, in Part 3, we highlight some of the controversies and unresolved issues, as well as suggest a general direction for future relaxin research that is urgently needed.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18161482     DOI: 10.1007/978-0-387-74672-2_6

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  30 in total

Review 1.  Cardiovascular effects of relaxin: from basic science to clinical therapy.

Authors:  Xiao-Jun Du; Ross A D Bathgate; Chrishan S Samuel; Anthony M Dart; Roger J Summers
Journal:  Nat Rev Cardiol       Date:  2009-11-24       Impact factor: 32.419

Review 2.  Medical therapy for acute decompensated heart failure: what recent clinical trials have taught us about diuretics and vasodilators.

Authors:  Catherine Marti; Robert Cole; Andreas Kalogeropoulos; Vasiliki Georgiopoulou; Javed Butler
Journal:  Curr Heart Fail Rep       Date:  2012-03

Review 3.  Novel vasodilators in heart failure.

Authors:  Payman Zamani; Barry H Greenberg
Journal:  Curr Heart Fail Rep       Date:  2013-03

4.  Potential influence of the corpus luteum on circulating reproductive and volume regulatory hormones, angiogenic and immunoregulatory factors in pregnant women.

Authors:  Kirk P Conrad; Georgia M Graham; Yueh-Yun Chi; Xiaoman Zhai; Minjie Li; R Stan Williams; Alice Rhoton-Vlasak; Mark S Segal; Charles E Wood; Maureen Keller-Wood
Journal:  Am J Physiol Endocrinol Metab       Date:  2019-08-13       Impact factor: 4.310

Review 5.  Are we getting closer to a Nobel prize for unraveling preeclampsia?

Authors:  Ralf Dechend; Friedrich C Luft
Journal:  Curr Cardiol Rep       Date:  2008-11       Impact factor: 2.931

Review 6.  Relaxin: review of biology and potential role in treating heart failure.

Authors:  Sam L Teichman; Elaine Unemori; John R Teerlink; Gad Cotter; Marco Metra
Journal:  Curr Heart Fail Rep       Date:  2010-06

7.  Pregnancy impairs baroreflex control of heart rate in rats: role of insulin sensitivity.

Authors:  Virginia L Brooks; Julia M Mulvaney; Afaf S Azar; Ding Zhao; Robert K Goldman
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2009-11-25       Impact factor: 3.619

8.  Relaxin-2 and Soluble Flt1 Levels in Peripartum Cardiomyopathy: Results of the Multicenter IPAC Study.

Authors:  Julie Damp; Michael M Givertz; Marc Semigran; Rami Alharethi; Gregory Ewald; G Michael Felker; Biykem Bozkurt; John Boehmer; Jennifer Haythe; Hal Skopicki; Karen Hanley-Yanez; Jessica Pisarcik; Indrani Halder; John Gorcsan; Sarosh Rana; Zoltan Arany; James D Fett; Dennis M McNamara
Journal:  JACC Heart Fail       Date:  2016-03-09       Impact factor: 12.035

Review 9.  Novel pharmacologic therapies in development for acute decompensated heart failure.

Authors:  Justin A Ezekowitz
Journal:  Curr Cardiol Rep       Date:  2013-02       Impact factor: 2.931

Review 10.  Relaxin, a pleiotropic vasodilator for the treatment of heart failure.

Authors:  Sam L Teichman; Elaine Unemori; Thomas Dschietzig; Kirk Conrad; Adriaan A Voors; John R Teerlink; G Michael Felker; Marco Metra; Gad Cotter
Journal:  Heart Fail Rev       Date:  2008-12-20       Impact factor: 4.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.